Radioimmunterapi
- Prosjektnummer
- 2008094
- Ansvarlig person
- Jostein Dahle
- Institusjon
- Oslo universitetssykehus HF
- Prosjektkategori
- Nytt flerårig forskningsprosjekt
- Helsekategori
- Cancer
- Forskningsaktivitet
- 5. Treatment Developement
Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.
PLoS One 2012;7(8):e42345. Epub 2012 aug 3
PMID: 22879947
Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
Nucl Med Commun 2012 Aug;33(8):838-47.
PMID: 22643311
Experimental a-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.
EJNMMI Res 2011;1(1):18. Epub 2011 aug 24
PMID: 22214432
Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates.
Curr Radiopharm 2011 Oct;4(4):321-8.
PMID: 22202154
Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab.
Int J Radiat Oncol Biol Phys 2011 Feb;79(2):563-70.
PMID: 21195878
Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab.
Eur J Nucl Med Mol Imaging 2010 Jan;37(1):93-102.
PMID: 19593562
In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab.
Int J Radiat Oncol Biol Phys 2009 Nov;75(3):886-95. Epub 2009 aug 11
PMID: 19679402
Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
Int J Radiat Oncol Biol Phys 2008 Sep;72(1):186-92.
PMID: 18722269
Targeted high-LET therapy of bone metastases.
Targeted radionuclide tumor therapy. Biological aspects. Editors: T. Stigbrand. J. Carlsson, G.P. Adams. Springer Verlag.(2008) ISBN: 978-1-420—8695-3.
Targeted alpha-particle therapy with 227Th-labeled antibodies.
Current radiopharmaceuticals. (2008) 1(3), 209-214.
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport